University of California, San Francisco

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).

1,713 total trials 272 currently recruiting 1130 completed early-phase tilt top decile by trial count

University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.

University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.

Top-decile sponsor footprint

University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 56/100

1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,713 total, page 29 of 35

COMPLETED NA

Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut

NCT00884793

COMPLETED NA

Internet Stop Smoking Study - Phase VI

NCT00721786

COMPLETED Phase 4

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

NCT00735072

COMPLETED NA

Intervention for (Those) Recently Informed of Seropositive Status (IRISS)

NCT00720733

TERMINATED

Motor Evoked Potentials and SedLine

NCT00805844

COMPLETED Phase 2

Omega-3 Fatty Acids for Autism Treatment

NCT00786799

COMPLETED

Evaluating Parental Influences on Obesity Among Mexican American Children

NCT00542672

COMPLETED Phase 1

A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas

NCT00734682

TERMINATED Phase 4

Statins and Endothelial Function in Patients With Coarctation of the Aorta

NCT00767572

TERMINATED NA

Computer-Assisted Treatment of Urinary Tract Infection in Emergency Departments and Community Health Centers

NCT00731315

TERMINATED Phase 2

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

NCT00632827

COMPLETED NA

Reducing Distress and Improving Self-Care in Diabetes

NCT00714441

COMPLETED NA

Vest Prevention of Early Sudden Death Trial and VEST Registry

NCT01446965

COMPLETED NA

Feeding During Ibuprofen or Indomethacin Treatment of Preterm Infants

NCT00728117

COMPLETED

Alzheimer's Family Research

NCT00878059

COMPLETED NA

Effects of Vitamin D on Lipids

NCT00723385

TERMINATED NA

Hydrogel Patch for the Treatment of Eczema

NCT00924508

COMPLETED NA

Deep Brain Stimulation in Patients With Dystonia

NCT00773604

COMPLETED Phase 3

Pain Medicine for Wound Care Procedures

NCT00701909

COMPLETED

Pharmacogenetics of Bupropion Metabolism

NCT00791869

COMPLETED NA

Effectiveness of Neuroadaptive Cognitive Training in Adolescents at Risk for Psychosis

NCT00655239

COMPLETED Phase 2

Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream

NCT00622440

COMPLETED NA

An Educational and Supportive Counseling Program for Increasing Antiretroviral Use and Adherence in People With HIV

NCT00611429

COMPLETED Phase 2

PTH & Ibandronate Combination Study (PICS)

NCT00683163

COMPLETED Phase 1

Radial Artery Dilation Study: The Effect of Topical Administration of Nitroglycerin and Lidocaine Versus Lidocaine Alone of the Radial Artery Diameter

NCT00686231

TERMINATED Phase 2

Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer

NCT00678015

COMPLETED NA

Impact of Extensive Consultation on Career Development Grant Outcomes

NCT00662402

COMPLETED NA

Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients

NCT00672932

COMPLETED Phase 4

Botox for Cervical Dystonia Following EMG Mapping

NCT00773253

COMPLETED Phase 1

Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications

NCT00877591

COMPLETED Phase 4

Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection

NCT00662545

COMPLETED Phase 3

Treating Tobacco Dependence in Adolescents With Co-occurring Psychiatric Disorders

NCT00618943

TERMINATED NA

Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery

NCT00644280

TERMINATED Phase 1

Prenatal Steroids for Treatment of Congenital Cystic Adenomatoid Malformations (CCAM)

NCT00670956

TERMINATED Early Phase 1

Effect of Timi3 Ultrasound on Myocardial Blow Flow in the Hibernating Myocardium

NCT00655070

COMPLETED

Effect of Endothelin-1 Receptor Blockade on Circulating Endothelial Microparticles Levels in Patients With Pulmonary Hypertension

NCT00675051

COMPLETED Phase 4

Treatment of Acute Hepatitis C Virus in HIV Co-Infection

NCT00845676

COMPLETED

Weight-Bearing Magnetic Resonance Imaging (MRI) for Analysis of Knee Osteoarthritis (OA)

NCT00665548

COMPLETED Phase 1

Influence of MMP on Brain AVM Hemorrhage

NCT00783523

COMPLETED NA

Bad Breath Response to Tongue Scraper and Rinses

NCT00867035

COMPLETED Phase 2

Web-Based Active Balance Childhood Study in Chinese-American

NCT00961246

COMPLETED

Phase I Targeting Dominant Intraprostatic Lesion Using MR Spectroscopy and HDR Brachytherapy

NCT00807820

COMPLETED Phase 1

Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers

NCT00626158

COMPLETED Phase 2

Reaching and Treating Lesbian, Gay, Bisexual, and Transgender (LGBT) Cigarette Smokers

NCT00634218

COMPLETED Phase 4

Raltegravir Intensification in HIV-infected Patients

NCT00631449

COMPLETED Phase 4

Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger

NCT00618449

COMPLETED NA

Alpha Lipoic Acid and Insulin Resistance

NCT00845156

COMPLETED

Dyspnea in Patients With Pulmonary Fibrosis

NCT00611182

COMPLETED

Mechanisms of Acute Asthma Exacerbations Through Molecular Analysis of Airway Secretions and Tissues

NCT00603629

COMPLETED NA

Craving and Lifestyle Management Through Mindfulness Pilot Study

NCT00643344

← Previous Page 29 of 35 Next →

Phase Distribution

PhaseTrial count
Phase 1 193
Phase 2 166
Phase 3 44
Phase 4 152

What is open in the University of California, San Francisco pipeline

272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).

Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (18 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, San Francisco: open-pipeline peers nationwide

Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.

University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share University of California, San FranciscoDuke UniversityStanford UniversityVA Office of Research and DevelopmentPfizerUniversity of OregonFox Chase Cancer CenterYoungstown State UniversityECOG-ACRIN Cancer Research Group
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,713 trials (± recruiting share)

Sponsors near 16% open enrollment (± trial volume)

What to do with this University of California, San Francisco page

1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.

  • 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.